Micheliolide CAS 68370-47-8
Introduction:Basic information about Micheliolide CAS 68370-47-8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Micheliolide Basic information
| Product Name: | Micheliolide |
| Synonyms: | (3aS)-3aβ,4,5,7,8,9,9aβ,9bα-Octahydro-9β-hydroxy-6,9-dimethyl-3-methyleneazuleno[4,5-b]furan-2(3H)-one;Micheliolide;[3aS-(3aalpha,9alpha,9aalpha,9bbeta)]-3a,4,5,7,8,9,9a,9b-Octahydro-9-hydroxy-6,9-dimethyl-3-methylene-azuleno[4,5-b]furan-2(3H)-one;Micheliolide, BR;CS-1321;Micheliolide 68370-47-8;Mecheliolide;Azuleno[4,5-b]furan-2(3H)-one, 3a,4,5,7,8,9,9a,9b-octahydro-9-hydroxy-6,9-dimethyl-3-methylene-, (3aS,9R,9aS,9bS)- |
| CAS: | 68370-47-8 |
| MF: | C15H20O3 |
| MW: | 248.32 |
| EINECS: | |
| Product Categories: | |
| Mol File: | 68370-47-8.mol |
Micheliolide Chemical Properties
| Melting point | 131-133 °C |
| Boiling point | 426.1±45.0 °C(Predicted) |
| density | 1.17±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Chloroform (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 14.65±0.40(Predicted) |
| color | Off-White |
| InChI | InChI=1S/C15H20O3/c1-8-4-5-11-9(2)14(16)18-13(11)12-10(8)6-7-15(12,3)17/h11-13,17H,2,4-7H2,1,3H3/t11-,12-,13-,15+/m0/s1 |
| InChIKey | RDJAFOWISVMOJY-PWNZVWSESA-N |
| SMILES | O1C(=O)C(=C)[C@]2([H])CCC(C)=C3[C@@]([H])([C@@]12[H])[C@@](O)(C)CC3 |
Safety Information
| Chemical Properties | Off-white powder, soluble in methanol, ethanol, DMSO and other organic solvents. | ||||||||||||||||||||||||||||
| Uses | Micheliolide, a sesquiterpene lactone is used in the inhibition of resistant acute leukemic cells. Selectively targets cancer stem and progenitor cells. | ||||||||||||||||||||||||||||
| Definition | ChEBI: Micheliolide is a sesquiterpene lactone. | ||||||||||||||||||||||||||||
| Biological Activity | Micheliolide (MCL) is a sesquiterpene lactone isolated from Michelia compressa and Michelia champaca. Previous studies have demonstrated that MCL exerted various therapeutic effects in cancer, inflammation, immunomodulatory acute myelogenous leukemia and renal fibrosis through numerous signaling pathways, including PI3K/Akt, NF-kB and MAPK signaling. Dimethylaminomicheliolide (DMAMCL), the prodrug of MCL, has been approved by the US Food and Drug Administration for its apparent efficacy in treating pleomorphic glioblastoma. In China, DMAMCL is currently undergoing clinical trials to treat several advanced or metastatic solid carcinomas, including gliomas[2]. | ||||||||||||||||||||||||||||
| in vivo | Micheliolide (10 or 20 mg/kg, i.p., a single dose for 2 h) attenuates the secretion of serum cytokines and protects against lung and liver tissue damage in LPS (10mg/kg, i.p., a single dose for 2 h)-challenged mice[2].
|
